Phase III Xeloda colon cancer study meets primary endpoint
Wednesday, May 12, 2004 12:00 IST Basel
Roche announced the successful conclusion of a large international phase III study comparing Xeloda with standard intravenous 5-FU/LV in the adjuvant treatment of early stage colon cancer